Products

Lung Density Analysis
IMBIO
Cardiology AI
IMBIO's Lung Density Analysis is an AI-driven medical imaging software that provides quantitative analysis and 3D visualization of lung conditions from CT scans, aiding in the diagnosis and management of diseases like COPD and emphysema. It offers automated workflows and detailed reports for personalized patient care.
Imbio RV/LV Software
Imbio
Cardiology AI
Imbio RV/LV Software is an AI-powered tool that automatically measures right and left ventricular diameters from CTPA scans, providing a ratio to aid in risk stratification for pulmonary conditions like pulmonary embolism.
Imbio PHA (4.0.0)
Imbio
Cardiology AI
Imbio PHA (4.0.0) is an FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.

See all 5 products →

About Imbio

Imbio, now a part of 4DMedical following its acquisition in December 2023, is a leading healthcare AI company specializing in advanced medical imaging analysis. The company’s solutions are designed to transform standard medical images, such as CT, MR, and X-ray scans, into rich visual maps and comprehensive quantitative reports. This technology empowers physicians with detailed, data-driven insights into a patient’s condition, enabling more precise diagnosis, personalized treatment planning, and effective therapy tracking for a range of acute and chronic cardiothoracic diseases.

For physicians, Imbio’s AI-powered algorithms offer fully automated 3D visualization and quantitative analysis, integrating seamlessly into existing clinical workflows. Their product suite addresses critical areas such as Lung Density Analysis (for emphysema and COPD), Lung Texture Analysis (for interstitial lung abnormalities), Pulmonary Hypertension Assessment, Airway Analysis, and Coronary Calcification. These tools aid in early disease detection, accurate disease staging, patient selection for interventions, and monitoring treatment response, ultimately enhancing diagnostic power and supporting improved patient outcomes.

The company’s commitment to physician-centric design ensures that its AI solutions are clinically relevant and easy to adopt, helping to bridge the gap between the vast information contained in medical images and the demands of modern healthcare. Imbio’s technology is utilized globally by radiologists, pulmonologists, and other specialists, and also supports medical device and pharmaceutical companies in clinical trials and drug development.

Focus Areas

AI-powered medical imaging analysis personalized lung care cardiothoracic care COPD emphysema lung fibrosis interstitial lung disease (ILD) lung cancer pulmonary hypertension airway analysis coronary artery calcification COVID-19/pneumonia severity

Business Intelligence

Key InvestorsInvenshure, HHS (Department of Health and Human Services), Angel Investors
Partnerships4DMedical (acquired Imbio), Blackford Analysis, MEDICAL-NOTE, Olympus Medical, 3DR Labs (Accumen Company), Aidoc, Siemens Healthineers, Genentech, Nuance AI Marketplace, Heart&Lung Health Ltd, Spesana, Flywheel, Wellbeing, TeraRecon, NTT DATA Services, GE Healthcare
AcquisitionsAcquired by 4DMedical on December 11, 2023, for an upfront purchase price of $25M.
TechnologyCloud-native (AWS), on-premise (VMware), web-based application, dockerized algorithms, machine learning, deep learning, automated workflows, 3D visualization, quantitative reporting, automated de-identification/re-identification, encrypted transmission
FDA Clearances3 cleared products (estimated)

What Physicians Need to Know

AI-Powered Medical Imaging Analysis
Imbio transforms standard medical images (CT, MR, X-ray) into rich visual maps and quantitative reports using machine learning and AI. This provides physicians with detailed data on the type and extent of abnormalities.
Personalized Lung Care
Specializes in comprehensive lung analysis, including Lung Density Analysis (LDAi for emphysema/COPD on inspiratory CT, LDAf for normal lung, air-trapping, and emphysema on paired inspiratory/expiratory CT), Lung Texture Analysis (LTA) for ILDs and fibrotic conditions, and Airway Analysis. These tools support personalized treatment planning from screening to therapy tracking.
Cardiothoracic Care
Offers solutions like RV/LV Analysis for pulmonary embolism and right ventricular dilation, and Coronary Artery Calcification (CAC) analysis to aid in the diagnosis and risk stratification of heart conditions.
COPD & Emphysema
Provides fully automated quantification of areas indicative of emphysema and COPD through Lung Density Analysis (LDAi and LDAf), aiding in diagnosis, staging, and patient selection for therapies like endobronchial valves.
Lung Fibrosis & ILD
Utilizes Lung Texture Analysis (LTA), based on CALIPER technology, to transform chest CTs into detailed maps and quantification of lung textures crucial for identifying Interstitial Lung Diseases (ILDs) and other fibrotic conditions.
Lung Cancer Screening Support
Imbio's algorithms, particularly LDAi, are validated for use with low-dose CT scans as a component of lung cancer screening programs, helping to identify and quantify emphysema in patient populations.
COVID-19/Pneumonia Severity
LDA+ provides quantification of airspace disease severity and extent, including areas potentially indicative of consolidation and ground glass, assisting in the diagnosis and assessment of COVID-19 or pneumonia severity.
Physician Tip

Imbio's solutions are designed to be fully automated, integrating seamlessly into existing workflows without requiring additional steps from physicians. This allows for rapid, quantitative analysis and 3D visualization of medical images, providing objective data that enhances diagnostic confidence, aids in disease staging, and supports personalized treatment decisions. The ability to quickly visualize and quantify abnormalities helps in early disease detection, monitoring treatment response, and improving overall patient care efficiency. Furthermore, Imbio's patient-centered reports, like the LungMapu2122, can facilitate patient education and counseling, particularly for initiatives like smoking cessation.

Imbio offers flexible deployment options, including Imbio Cloud (AWS-based) or Imbio Enterprise (on-premise VMware) platforms. Their dockerized algorithms can also be delivered through various partner platforms. Imbio integrates with major radiology reporting systems and AI marketplaces, such as Nuance AI Marketplace (PowerScribe), Siemens syngo.via, GE Health Cloud, Blackford Platform, Aidoc, TeraRecon, and FerrumHealth, ensuring that analysis outputs (3D DICOM series and quantitative reports) are automatically sent to PACS and available within existing clinical environments.

Products by Imbio

5 products in the directory

Lung Density Analysis
IMBIO
Cardiology AI
IMBIO's Lung Density Analysis is an AI-driven medical imaging software that provides quantitative analysis and 3D visualization of lung conditions from CT scans, aiding in the diagnosis and management of diseases like COPD and emphysema. It offers automated workflows and detailed reports for personalized patient care.
Imbio RV/LV Software
Imbio
Cardiology AI
Imbio RV/LV Software is an AI-powered tool that automatically measures right and left ventricular diameters from CTPA scans, providing a ratio to aid in risk stratification for pulmonary conditions like pulmonary embolism.
Imbio PHA (4.0.0)
Imbio
Cardiology AI
Imbio PHA (4.0.0) is an FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.
CAC Software
Imbio
Cardiology AI
Imbio's Coronary Artery Calcification (CAC) software is a set of automated image post-processing algorithms designed to help radiologists and cardiologists determine the location and calculate the amount of calcification within the coronary arteries in patients who have undergone a non-contrast, chest computed tomography (CT).
IQ-UIP
Imbio
Clinical Decision Support & Reference
Imbio IQ-UIP is an FDA-cleared AI tool that analyzes chest CT scans to identify findings suspicious for Usual Interstitial Pneumonia (UIP) patterns, providing quantitative reports to aid specialists in diagnosing interstitial lung diseases.

Reviews & Opinions

No web reviews on file yet for Imbio. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Imbio.

Loading videos...

Videos load interactively. If none appear, search YouTube for Imbio →

View all on YouTube

Press & Coverage

HealthCare Business News
4D Medical to acquire AI developer Imbio, expanding lung CT analytics capabilities
4D Medical is set to acquire AI algorithm developer Imbio for up to $45 million, including an upfront payment and contingent payments, to expand its CT analytics capabilities for lung characteristics. The acquisition aims to combine 4DMedical's functional analysis with Imbio's anatomical and tissue analysis to create a leading lung imaging AI suite.
2023-12
Imbio (via PRNewswire)
Imbio to be Acquired by 4DMedical Creating Comprehensive Cardiothoracic Image Analysis Portfolio
Imbio, a provider of medical imaging analysis technologies, announced a binding agreement to be acquired by 4DMedical, aiming to create a comprehensive cardiothoracic image analysis portfolio. The combined offering will provide functional, structural, and risk-based analysis for both lung and heart disease from standard chest CTs.
2023-12
Imbio (via Radiology Today)
Radiology Today: Deep Breathsu2014New Technology Offers Hope for Veterans Who Were Exposed to Burn Pits
An article in the American Journal of Respiratory and Critical Care Medicine highlights how parametric response mapping, a chest CT image analysis technique commercially available from Imbio (a subsidiary of 4DMedical), can identify air-trapping patterns in veterans exposed to burn pits. This technology provides a functional picture of the lung, useful for assessing conditions like constrictive bronchiolitis and COPD.
2024-04
Imbio (via PRNewswire)
Imbio Receives FDA 510(k) Clearance for New Cardiothoracic Imaging Algorithm
Imbio received U.S. Food and Drug Administration (FDA) 510(k) clearance for its RV/LV Analysisu2122 algorithm, an AI-driven tool for rapid, automated assessment of potential right ventricular dilation. This algorithm provides a key patient risk indicator for various pulmonary conditions such as pulmonary embolism.
2021-03
Imbio (via PRNewswire)
Imbio and Riverain Technologies Partner to Offer a Comprehensive AI-Powered Lung Health Solution
Imbio and Riverain Technologies announced a partnership to offer a comprehensive AI-powered lung health solution, combining Imbio's expertise in chronic lung and cardiothoracic diseases with Riverain's clinical AI for lung nodules. This collaboration aims to enhance the detection and management of lung conditions.
2021-05
PR Newswire
Imbio Partners with MEDICAL-NOTE to Expand Image Analysis Tool Offering to Clinicians across Italy
Imbio partnered with MEDICAL-NOTE to expand access to Imbio's AI technologies across Italy, providing valuable quantitative imaging data to surgeons, pulmonologists, and radiologists through MEDICAL-NOTE applications. This collaboration aims to support various clinical initiatives like lung cancer screening and pulmonary embolism management.
2021-09
Imbio (via PRNewswire)
Imbio Partners with Genentech to Develop Imaging Diagnostics for Lung Diseases
Imbio announced a multi-year partnership with Genentech, a member of the Roche Group, to develop quantitative imaging diagnostics for lung diseases. This collaboration will leverage Imbio's expertise in imaging biomarkers and Genentech's pulmonary disease knowledge to create and deploy medical imaging AI algorithms.
2020-10
Imbio (via PRNewswire)
National Institute for Health and Care Excellence (NICE) releases Medtech Innovation Briefing (MIB) for Imbio's Lung Texture Analysis Algorithm
The National Institute for Health and Care Excellence (NICE) released a Medtech Innovation Briefing (MIB) for Imbio's Lung Texture Analysis Algorithm. This briefing provides evidence-based recommendations for the technology, which performs three-dimensional segmentation and classifies lung voxels into radiological categories.
2021-09

Frequently Asked Questions

Imbio's AI solutions provide quantitative analysis and visualization for a range of lung and cardiothoracic conditions. These include Chronic Obstructive Pulmonary Disease (COPD), emphysema, lung fibrosis, interstitial lung disease (ILD), lung cancer screening, pulmonary hypertension, airway analysis, and coronary artery calcification. The technology also assists in assessing the severity of COVID-19 and pneumonia.
Imbio's algorithms are designed for seamless, automated integration into clinical workflows, receiving images from scanners via DICOM and sending results to PACS. Deployment options include Imbio Cloud, an on-premise Enterprise platform, or integration through partners like Nuance and Siemens syngo.via. Many of Imbio's products, such as Lung Density Analysis and RV/LV Analysis, have received FDA 510(k) clearance and CE Mark certification.
Yes, Imbio's AI solutions provide rich quantitative data and visualizations to aid in accurately staging disease, supporting treatment decisions, and tracking patient progress for personalized care. Products like Lung Density Analysis (LDAi and LDAf) quantify COPD and emphysema severity, while Lung Texture Analysis (LTA) assists in ILD diagnosis and therapy response. LDA+ is specifically designed to assess COVID-19 or pneumonia severity.
While specific pricing models are not publicly detailed, Imbio aims to offer a cost-effective way to integrate their AI applications without significant additional infrastructure investment. Imbio provides comprehensive 24/7/365 technical support to all customers globally, accessible via phone and email, including an online case submission system. Support also includes access to user manuals and product documentation upon request.
Imbio has strategic partnerships with key industry players like Siemens Healthineers, Genentech, Riverain Technologies, and Blackford Analysis to enhance product development and market reach. In December 2023, Imbio was acquired by 4DMedical, significantly bolstering its lung imaging technologies and expanding its comprehensive cardiothoracic imaging portfolio. This acquisition underscores Imbio's strong market position and long-term stability.
Yes, Imbio's algorithms support clinical initiatives such as lung cancer screening programs by providing quantitative insights from CT scans. Their FDA-cleared RV/LV Analysis algorithm offers a rapid, automated assessment of right ventricular dilation, which is a crucial risk indicator for pulmonary conditions like pulmonary embolism and aids in risk stratification for pulmonary hypertension.
Imbio's Airway Analysis solution provides fully automated measurements of airway structures, including lumen and total airway diameters, and wall thickness, though it is currently for investigational use. For cardiothoracic care, their FDA-cleared Coronary Artery Calcification (CAC) analysis uses AI to quantify calcification from non-contrast chest CTs, offering objective quantification, 3D visualization, and artery-specific scoring to differentiate cardiac from pulmonary causes of dyspnea.

Related Companies

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare AI company dedicated to solving the healthcare affordability crisis for both patients and providers. The company’s AI-powered platform offers personalized, interest-free, and fee-free patient financing solutions, enabling patients to manage their medical bills through affordable payment plans tailored to their unique ability to pay. This approach aims to increase access to […]

Healthcare Finance.AI is a company dedicated to leveraging cutting-edge artificial intelligence to optimize healthcare revenue cycles. Their goal is to improve financial outcomes for healthcare providers while simultaneously supporting the industry’s commitment to quality care and efficiency. They aim to achieve this by enhancing healthcare finance through AI innovation, demonstrating increased revenue cycle efficiency, reducing […]

The American Academy of Family Physicians (AAFP) is one of the largest national medical organizations in the United States, representing over 130,000 family physicians, residents, and medical students. Founded in 1947, its core mission is to improve the health of patients, families, and communities by serving the needs of its members with professionalism and creativity. […]

Imperial College Business School is a global business school that is part of Imperial College London, a top-ranking science-based institution. Established in 2004, the school integrates business and entrepreneurship with technology. Its roots in business education trace back to 1955 with an operational research/management science course. The school is triple-crown accredited (AACSB, AMBA, EQUIS), placing […]

Columbia University, through its online learning initiative ColumbiaX on edX, offers a range of courses, including those focused on healthcare AI. The university is a global leader in research, teaching, and public impact, consistently ranked among top universities. Their online offerings reflect a commitment to academic excellence and expanding access to high-quality education worldwide. For […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.